Data by Industry within Healthcare Sector
|
| |
Marketcap |
Revenues (TTM) |
Net Income (TTM) |
Employees |
| Industry |
(Millions) |
(Millions) |
(Millions) |
Number |
| Biotechnology & Pharmaceuticals Industry |
$ 646,789 |
$ 98,468 |
$ -15,686 |
88,454 |
| Healthcare Facilities Industry |
$ 286,446 |
$ 210,297 |
$ 9,058 |
1,124,696 |
| Major Pharmaceutical Preparations Industry |
$ 4,206,497 |
$ 733,517 |
$ 52,514 |
1,140,057 |
| Medical Equipment & Supplies Industry |
$ 1,300,121 |
$ 307,843 |
$ 18,040 |
820,084 |
| Medical Laboratories Industry |
$ 286,391 |
$ 94,617 |
$ 1,833 |
451,438 |
| Laboratory Analytical Instruments Industry |
$ 158,115 |
$ 31,174 |
$ -3,324 |
76,934 |
| In Vitro & In Vivo Diagnostic Substances Industry |
$ 71,170 |
$ 10,972 |
$ 76 |
19,994 |
| Healthcare Sector |
$ 6,955,530 |
$ 1,486,889 |
$ 62,512 |
3,721,657 |
Recent News from Healthcare Sector |
|
Merger and Acquisition
Breaking News BOSTON and LONDON, Oct. 15, 2024 ? In a significant development for the biotechnology sector, Akari Therapeutics, Plc (Nasdaq: AKTX) has announced the effectiveness of its Form S-4, originally filed with the Securities and Exchange Commission (SEC) on September 13, 2024. This pivotal form, which facilitates the merger between Akari Therapeut...
|
|
|
Stock Market Announcement
DALLAS, Oct. 14, 2024 ?? In a noteworthy development for the medical diagnostics sector, Spectral AI, Inc. (Nasdaq: MDAI), an artificial intelligence company dedicated to enhancing treatment decisions in wound care, has announced the return of its founder, Dr. J. Michael DiMaio, as the Chairman of the Board of Directors. This strategic appointment marks a...
|
|
|
Financing Agreement
In a significant development that underscores the dynamic nature of the emerging psychedelic sector, Psyence Group Inc. (Psyence Group or the Company) has recently announced a debt-for-equity swap agreement with its NASDAQ-listed associate, Psyence Biomedical Ltd. (NASDAQ: PBM) (Psyence Biomed). This strategic maneuver, unveiled on October 14, 2024, refle...
|
|
|
Merger and Acquisition
In a watershed moment for the biotech industry, INVO Bioscience and NAYA Biosciences have successfully completed their long-anticipated merger, resulting in the creation of a formidable new entity that will operate under the name NAYA Biosciences (NASDAQ: NAYA). This merger represents a significant consolidation of expertise, resources, and innovation cap...
|
|
|
Stock Market Announcement
NewGenIvf Faces Nasdaq Compliance Challenge While Pioneering Fertility Advancements in AsiaNewGenIvf Group Limited (NASDAQ: NIVF), a forward-thinking company in the fertility solutions sector, recently announced a significant development regarding its status on the Nasdaq Stock Market. On October 8, 2024, the company received a letter from the Listing Qua...
|
|
|
Shares
In a move aimed at enhancing shareholder value and bolstering its market presence, Sharps Technology, Inc. (NASDAQ: STSS) has announced an upcoming one-for-22 reverse stock split of its common stock, set to take effect on October 15, 2024, at 11:59 PM Eastern Time. This pivotal decision, which comes as the company embarks on a series of strategic initiati...
|
|
|
Shares
23andMe to Undergo Significant Financial Restructuring with Reverse Stock SplitIn a strategic move aimed at consolidating its market presence, 23andMe Holding Co. (Nasdaq: ME) has announced a 1-for-20 reverse stock split for its Class A and Class B common stock. This financial maneuver is set to take effect at 12:01 a.m. EST on October 16, 2024. The deci...
|
|
|
Dividend
Royalty Pharma Declares Fourth Quarter Dividend Amid Strategic Partnerships and Market FluctuationsNEW YORK, Oct. 11, 2024 ?? Royalty Pharma plc (Nasdaq: RPRX) has announced a fourth-quarter dividend of $0.21 per Class A ordinary share, underscoring the company's commitment to shareholder returns even as it navigates a turbulent market landscape.The annou...
|
|
|
Shares
Aligos Therapeutics Expands Talent Pool with Strategic Stock Options Amid MASH Treatment Innovations'By , Contributor'SOUTH SAN FRANCISCO, Calif., Oct. 11, 2024 ?? In a bold move signaling its commitment to fostering innovation in the biopharmaceutical sector, Aligos Therapeutics, Inc. has announced substantial stock option grants to new employees as par...
|
|
|
Management Announcement
NMPA Approval of First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer Comes Amidst Financial Turbulence for Burning Rock BiotechIn a landmark achievement for the intersection of healthcare and technological innovation, the National Medical Products Administration (NMPA) in China has granted marketing approval for the first co-developed next-g...
|
|
|
Management Announcement
In a move marking a pivotal moment for Procaps Group, S.A. (NASDAQ: PROC), the Latin American healthcare and pharmaceutical giant has navigated a course of strategic restructuring that promises to bolster its position amidst industry challenges. Recent communications from CEO Jos Antonio Vieira have outlined the company's strategic vision, addressing the ...
|
|
|
Stock Market Announcement
Bio-Path Holdings Secures $4.0 Million in Recent Private Placement: An Analysis of Their Financial Maneuvers and Market Position Bio-Path Holdings, Inc. (NASDAQ: BPTH), a Houston-based biotechnology company focused on developing innovative targeted nucleic acid cancer therapies with its proprietary DNAbilize liposomal delivery and antisense technology, ...
|
|
|
Shares
Crinetics Pharmaceuticals Welcomes New Talent Amid Strategic Moves and Public Offering PlansSAN DIEGO, Oct. 10, 2024 ?? In a series of calculated strategic maneuvers, Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) has announced several significant developments focusing on talent acquisition and financial offerings that could have substantial implications...
|
|
|
Stock Market Announcement
Tempest Therapeutics Extends Its Stockholder Rights Plan: What It Means for InvestorsOn October 10, 2024, Tempest Therapeutics, Inc. (Nasdaq: TPST), a rising star in the biotechnology sector focusing on innovative cancer therapies, announced a significant amendment to its existing limited duration stockholder rights plan. This strategic decision by the co...
|
|
|
Shares
Unlocking Visionary Growth: Ocular Therapeutix's Strategic Inducement GrantIn the evolving sphere of biopharmaceutical companies, Ocular Therapeutix, Inc. (NASDAQ: OCUL) stands out as a trailblazer, pioneering innovative therapies for retinal diseases and various eye conditions. The Bedford, Massachusetts-based firm is not only committed to improving visi...
|
|
|
Financing Agreement
Replimune Group, Inc.: Advancing Oncolytic Immunotherapy Amidst Financial Growth and Strategic Investor EngagementWOBURN, Mass., October 9, 2024 ?? Replimune Group, Inc. (NASDAQ: REPL), a pioneering clinical-stage biotechnology company specializing in innovative oncolytic immunotherapies, has made headlines once again, this time announcing a series of in...
|
|
|
Business Update
'Championing Antiviral Innovation: Gilead Sciences at IDWeek 2024'FOSTER CITY, Calif. ?? As the global biotechnology leader Gilead Sciences Inc. prepares to take center stage at IDWeek 2024, anticipation builds around the transformative potential of its antiviral research portfolio. From October 16-19, medical professionals and researchers worldwide will ...
|
|
|
Business Update
'Building Success: Henry Shines as The Home Depot's Building Materials Partner of the Year Again'In the dynamic world of construction and building innovation, Carlisle Companies Incorporated is making waves. Based in Scottsdale, Arizona, Carlisle has reason to celebrate as one of its standout subsidiaries, Henry, has been named The Home Depot's Building M...
|
|
|
Shares
In a significant move for the biopharmaceutical sector, Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage company focused on developing innovative therapies targeting cardiopulmonary and neurodegenerative diseases, has announced the pricing of a $110 million private placement. This financial boost will enable the company to advance its promisi...
|
|
|
Management Announcement
In the ever-evolving landscape of biopharmaceutical innovation, hope often hinges on the breakthroughs of tomorrow. Capricor Therapeutics, a pioneering company in the realm of advanced therapeutic modalities, has announced an exciting development that could significantly impact the lives of individuals suffering from Duchenne Muscular Dystrophy (DMD) card...
|
|
|
Clinical Study
In the ever-evolving landscape of oncology, the role of specific targets in overcoming cancer's complex mechanisms is paramount. Recently, Kronos Bio made significant strides in this arena, presenting compelling data at the EORTC-NCI-AACR Symposium that underlined the therapeutic potential of p300 KAT inhibition in human papillomavirus (HPV)-driven tumors...
|
|
|
Business Update
Verastem Oncology, a committed biopharmaceutical entity focused on advancing innovative cancer therapies, has recently made significant strides in the ongoing fight against cancer. The company has announced upcoming details for the oral presentation of its mature data from the RAMP 201 clinical trial, specifically evaluating the combination of two promisi...
|
|
|
Business Update
'Schrödinger Set to Showcase Promising Preclinical Data on SGR-3515 and PRMT5-MTA at EORTC-NCI-AACR Symposium Amid Impressive Revenue Growth'In an exciting development within the biopharmaceutical sector, Schrödinger Inc. (Nasdaq: SDGR) has announced it will present new preclinical data regarding its investigational compounds SGR-3515 and the PRMT5-MTA in...
|
|
|
Business Update
In a rapidly evolving healthcare landscape, Ontrak Health, Inc. (NASDAQ: OTRK), a prominent player in AI-powered behavioral health solutions, has recently announced an expansion of its strategic partnership with a significant regional health plan in the Northeast. This collaboration aims to leverage Ontrak's innovative Ontrak Quality solution to target ca...
|
|
|
Business Update
Marinus Pharmaceuticals, Inc., a trailblazer in the development of innovative treatments for seizure disorders, has made significant strides recently, showcasing its commitment to advancing therapies for patients in need. Three pivotal announcements provide a comprehensive insight into the company?s evolving landscape.'1. Prominent Presentations at Neuro...
|
|
|
Business Update
'Summary'Exscientia plc, a leader in artificial intelligence-driven drug discovery, is poised to present significant new preclinical findings concerning its LSD1 and MALT1 inhibitors at the upcoming 36th EORTC-NCI-AACR (ENA) Symposium 2024, scheduled for October 23-25 in Barcelona, Spain. These developments mark a significant step forward in Exscientia's ...
|
|
|
Business Update
AbstractPreeclampsia, a complex hypertensive disorder occurring during pregnancy, poses significant risks to maternal and fetal health. New therapeutic strategies to address this condition are urgently needed. DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on severe ischemic diseases, has recently received regulatory appr...
|
|
|
Business Update
'Harnessing Innovation in Oncology: Arcus Biosciences Poised to Unveil Pioneering ARC-20 Study Data at the 2024 EORTC-NCI-AACR Symposium''HAYWARD, Calif.' ?? A beacon of innovative cancer research, Arcus Biosciences, Inc. (NYSE: RCUS), is preparing to make significant waves at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics....
|
|
|
Business Update
'Ambulnz by DocGo and Bayhealth Renew Partnership in Delaware for Three More Years'DocGo Inc. (NASDAQ: DCGO), an innovative leader in technology-enabled mobile health services, has announced an important renewal in its operations within Delaware. The company's subsidiary, Ambulnz, has entered into a three-year contract extension with Bayhealth, the larges...
|
|
|
Business Update
'NATICK, Mass.' ?? Allurion Technologies, Inc. (NYSE: ALUR), a pioneering company in the battle against obesity, has announced significant findings from a recent study published in the journal 'Clinical Obesity'. The study sheds light on the effects of the Allurion Program, particularly focusing on weight reduction and body composition changes in patients...
|
|
|
|
|
|
